Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$7.55 ▼ -0.02
(-0.26%)
MKT CAP: $94.8M • VOL: 90.6K
52W L $2 52W H $9
NRXS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $3.6M | $2.7M | $2.5M |
| YoY Revenue Growth % | +32.9% | +9.2% | — |
| Gross Profit | $3.0M | $2.3M | — |
| Gross Margin % | 84.2% | 86.5% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.8M | -$7.2M | -$6.7M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$7.8M | -$8.2M | -$14.6M |
| EBITDA (Normalized) | -$7.8M | -$7.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.4M | -$6.1M | -$6.7M |
| Capital Expenditures (CapEx) | $31.1K | $27.8K | — |
| Free Cash Flow (FCF) | -$6.5M | -$6.1M | -$6.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.0M | $3.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $3.4M | $2.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NRXS.